Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 1, 2009, Pages 171-181

  Meyer, Todd ^a   Robles Carrillo, L ^a   Robson, T ^a   Langer, F ^b   Desai, H ^a   Davila, M ^a   Amaya, M ^a   Francis, J L ^a   Amirkhosravi, A ^a  

^a FLORIDA HOSPITAL   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Bevacizumab; Heparin induced thrombocytopenia; Thrombosis

Indexed keywords

ADENOSINE DIPHOSPHATE; BEVACIZUMAB; FC RECEPTOR IIA; HEPARIN; THROMBIN; VASCULOTROPIN; VASCULOTROPIN 165;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOTTING; COMPLEX FORMATION; CONTROLLED STUDY; DEGRANULATION; HYPERCOAGULABILITY; IMMUNE COMPLEX DEPOSITION; IN VIVO STUDY; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM; THROMBOSIS; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY COMPLEX; HEPARIN; MICE; MICE, TRANSGENIC; PLATELET ACTIVATION; RECEPTORS, IGG; THROMBOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 57749207937     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03212.x     Document Type: Article

References (35)

1. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, Hurwitz H. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99: 1232-9.
2. Barnard K. Viewpoint: An explanation for the cardiovascular effects of bevacizumab and rofecoxib? Circulation 2006; 114: 173-6.
3. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005; 65: 671-80.
4. Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 2003; 21: 3542.
5. Zondor SD, Medina PJ. Bevacizumab: An angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother 2004; 38: 1258-64.
6. Kuenen BC, Levi M, Meijers JC, van Hinsbergh VW, Berkhof J, Kakkar AK, Hoekman K, Pinedo HM. Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. J Clin Oncol 2003; 21: 2192-8.
7. Ma L, Francia G, Viloria-Petit A, Hicklin DJ, du Manoir J, Rak J, Kerbel RS. In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: Modulation by lower-dose chemotherapy. Cancer Res 2005; 65: 5365-73.
8. Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843-50.
9. Ryan AM, Eppler DB, Hagler KE, Bruner RH, Thomford PJ, Hall RL, Shopp GM, O'Neill CA. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol Pathol 1999; 27: 78-86.
10. Gerber HP, Hillan KJ, Ryan AM, Kowalski J, Keller GA, Rangell L, Wright BD, Radtke F, Aguet M, Ferrara N. VEGF is required for growth and survival in neonatal mice. Development 1999; 126: 1149-59.
11. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76.
12. Gerber HP, Wu X, Yu L, Wiesmann C, Liang XH, Lee CV, Fuh G, Olsson C, Damico L, Xie D, Meng YG, Gutierrez J, Corpuz R, Li B, Hall L, Rangell L, Ferrando R, Lowman H, Peale F, Ferrara N. Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci U S A 2007; 104: 3478-83.
13. Langer F, Ingersoll SB, Amirkhosravi A, Meyer T, Siddiqui FA, Ahmad S, Walker JM, Amaya M, Desai H, Francis JL. The role of CD40 in CD40L- and antibody-mediated platelet activation. Thromb Haemost 2005; 93: 1137-46.
14. US Patent Application #20060062784, Paragraph #229: http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2= HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r= 1&f=G&l=50&co1=ANDd=PG01&s1=20060062784&OS= 20060062784&RS=20060062784 (Accessed July 2008).
15. Warkentin TE. Management of heparin-induced thrombocytopenia: A critical comparison of lepirudin and argatroban. Thromb Res 2003; 110: 73-82.
16. Ginsberg MH, Henson PM. Enhancement of platelet response to immune complexes and IgG aggregates by lipid A-rich bacterial lipopolysaccharides. J Exp Med 1978; 147: 207-17.
17. Meyer T, Robson T, Amirkhosravi A, Langer F, Desai H, Amaya M, Elias P, Francis JL. Targeting angiogenesis in cancer: Bevacizumab-induced platelet activation as a possible cause for unexpected arterial thromboembolic events in clinical trials. Blood 2006; 108: 325a.
18. McKenzie SE, Taylor SM, Malladi P, Yuhan H, Cassel DL, Chien P, Schwartz E, Schreiber AD, Surrey S, Reilly MP. The role of the human Fc receptor Fc gamma RIIA in the immune clearance of platelets: A transgenic mouse model. J Immunol 1999; 162: 4311-8.
19. Taylor SM, Reilly MP, Schreiber AD, Chien P, Tuckosh JR, McKenzie SE. Thrombosis and shock induced by activating antiplatelet antibodies in human Fc gamma RIIA transgenic mice: The interplay among antibody, spleen, and Fc receptor. Blood 2000; 96: 4254-60.
20. Horne MK 3rd, Hutchison KJ. Simultaneous binding of heparin and platelet factor-4 to platelets: Further insights into the mechanism of heparin-induced thrombocytopenia. Am J Hematol 1998; 58: 24-30.
21. Cines DB, Rauova L, Arepally G, Reilly MP, McKenzie SE, Sachais BS, Poncz M. Heparin-induced thrombocytopenia: An autoimmune disorder regulated through dynamic autoantigen assembly/disassembly. J Clin Apher 2007; 22: 31-6.
22. Greinacher A, Gopinadhan M, Günther JU, Omer-Adam MA, Strobel U, Warkentin TE, Papastavrou G, Weitschies W, Helm CA. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscler Thromb Vasc Biol 2006; 26: 2386-93.
23. Ferrant JL, Wilson CA, Benjamin CD, Hess DM, Hsu YM, Karpusas M, Roux KH, Taylor FR. Variation in the ordered structure of complexes between CD154 and anti-CD154 monoclonal antibodies. Mol Immunol 2002; 39: 77-84.
24. Santora LC, Kaymakcalan Z, Sakorafas P, Krull IS, Grant K. Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore. Anal Biochem 2001; 299: 119-29.
25. Kut C, Mac Gabhann F, Popel AS. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer 2007; 97: 978-85.
26. Horsewood P, Hayward CP, Warkentin TE, Kelton JG. Investigation of the mechanisms of monoclonal antibody-induced platelet activation. Blood 1991; 78: 1019-1026
27. Polgár J, Eichler P, Greinacher A, Clemetson KJ. Adenosine diphosphate (ADP) and ADP receptor play a major role in platelet activation/aggregation induced by sera from heparin-induced thrombocytopenia patients. Blood 1998; 91: 549-54.
28. Brandt JT, Isenhart CE, Osborne JM, Ahmed A, Anderson CL. On the role of platelet Fc gamma RIIa phenotype in heparin-induced thrombocytopenia. Thromb Haemost 1995; 74: 1564-72.
29. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902-7.
30. Bikfalvi A. Recent developments in the inhibition of angiogenesis: examples from studies on platelet factor-4 and the VEGF/VEGFR system. Biochem Pharmacol 2004; 68: 1017-21.
31. Bergsland EK. When does the presence of the target predict response to the targeted agent? J Clin Oncol 2006; 24: 213-6.
32. Verheul HM, Lolkema MP, Qian DZ, Hilkes YH, Liapi E, Akkerman JW, Pili R, Voest EE. Platelets take up the monoclonal antibody bevacizumab. Clin Cancer Res 2007; 13: 5341-7.
33. Heinzerling JH, Huerta S. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: Incidence, etiology, and management. Curr Surg 2006; 63: 334-7.
34. Danese S, Scaldaferri F, Vetrano S, Stefanelli T, Graziani C, Repici A, Ricci R, Straface G, Sgambato A, Malesci A, Fiocchi C, Rutella S. Critical role of the CD40 CD40-ligand pathway in regulating mucosal inflammation-driven angiogenesis in inflammatory bowel disease. Gut 2007; 56: 1248-56.
35. Barron H. 2005. Important Drug Warning. http://www.fda.gov/medwatch/ safety/2005/Avastin_dearhcp.pdf (Accessed July 2008).